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Introduction
TCZ, an IL-6R inhibitor, is effective in systemic and
polyarticular juvenile idiopathic arthritis (sjia, pjia). BW-
adjusted, intravenous dosing regimens (TCZ8 mg/kg
Q2W for sjia and Q4W for pjia) were assessed in Japanese
phase 3 trials. As shown in Results, BW adjustment led to
lower TCZ exposure with lower BW; thus, higher doses
were proposed for patients (pts) with BW<30 kg in the
global TENDER (sjia) and CHERISH (pjia) trials.
Objectives
To describe the PK, PD and exposure-efficacy/-safety
relationships of adjusted BW-based TCZ therapy in sjia/
pjia pts.
Methods
PK/PD results were summarised in TCZ-treated pts
from part 1 of TENDER and CHERISH. TENDER part
1 (n = 75) comprised a 12-wk, double-blind phase with
pts randomised 1:1 to TCZ or placebo Q2W; TCZ 12
mg/kg if <30 kg and 8 mg/kg if ≥30 kg. CHERISH part
1 (n = 177) comprised a 16-wk TCZ Q4W open-label
phase (TCZ 8 mg/kg if ≥30 kg and 8 mg/kg or 10 mg/kg
randomised if <30 kg). Pts were 2-17 y old with ≥5 active
joints and >38°C fever for ≥5 days (sjia) or ≥3 of ≥5 joints
with limited motion (pjia). Blood samples were analysed
for TCZ, IL-6R blockade markers (IL-6, soluble IL-6R
[sil-6R]), C-reactive protein (CRP) levels and erythrocyte
sedimentation rate (ESR). Efficacy was measured as JIA
ACR30/50/70/90 response rates. Population PK (poppk)
modelling was used to further analyse serum TCZ
concentration data in addition to descriptive summary
statistics.
Results
In sjia pts, mean serum TCZ concentrations over time
and steady state TCZ exposures at wk 12 were similar
between TCZ 8 mg/kg and 12 mg/kg BW groups. Predose
concentrations trended upwards over time, stabilising by
wks 10-12. IL-6, sil-6R, CRP and ESR profiles were over-
laid between BW groups, showing similar IL-6R blockade.
Consistently, primary efficacy outcomes by JIA ACR 70/90
response were also comparable. In pjia pts, the <30 kg
group taking TCZ 8 mg/kg had lower TCZ concentrations
than the <30 kg group taking 10 mg/kg and the ≥30 kg
taking 8 mg/kg, which were similar to each other. IL-6,
sil-6R, CRP and ESR profiles indicated reduced IL-6R
blockade in pts <30 kg taking TCZ 8 mg/kg than in the
other two groups. Consistent with this, quartile analysis
showed lower JIA ACR30/50/70/90 response rates at wk
16 in the lowest TCZ exposure quartile. No clear trends in
adverse events across exposure quartiles were seen in sjia
or pjia pts. Poppk analysis showed similar linear clearance
of TCZ in sjia and pjia pts, but the Michaelis-Menten
constant in target-mediated clearance was 3-4× higher in
sjia pts.
Conclusion
Results support adjusting BW-based TCZ dosing in sjia/
pjia pts with the optimal dosages: sjia, TCZ 12 mg/kg
Q2W for BW<30 kg and 8 mg/kg Q2W for BW≥30 kg;
pjia, TCZ 10 mg/kg Q4W for BW<30 kg and 8 mg/kg
Q4W for BW≥30 kg. Taking into consideration compar-
able linear clearances in sjia/pjia pts, the higher Michaelis-
Menten constant in target-mediated clearance for sjia pts
may be due to higher cell surface IL-6R levels.
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Observations are consistent with higher baseline IL-6
signalling in sjia pts and potentially explain the need
for higher dose regimens to saturate IL-6R for optimal
therapy in sjia pts.
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